• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Remy Cointreau cuts sales outlook as US, China weigh on Q2

by October 25, 2024
written by October 25, 2024

By Dominique Vidalon

PARIS (Reuters) -French spirits maker Remy Contreau on Friday dropped its forecast that its full-year sales would gradually recover after quarterly sales fell more than expected amid worsening market conditions in China and uncertainty over the timing of a recovery in the U.S.

The company producing Remy Martin cognac and Cointreau liqueur said it now expected a double-digit fall in organic sales for the year, also impacting its profit margin.

Remy reported group sales of 318 million euros ($344.14 million) in the July-September quarter of its 2024/25 financial year ending on March 31, down by 16.1%. Analysts had predicted a 15.4% decline.

Cognac sales alone fell 20.7% in the quarter against analysts expectations of an 18% drop.

Remy Cointreau makes some 70% of sales from cognac, with the vast majority of those in the U.S. and Chinese markets.

A tough economy is hitting consumer demand in China while excessive inventories in the United States weigh on producers.

In China, cognac makers like Remy also face temporary anti-dumping measures, which Beijing imposed on brandy imports from the European Union earlier this month.

Remy said that if the Chinese decision was confirmed, its impact would be marginal for fiscal year 2024/25, and it would activate its action plan to mitigate the effects from 2025/26.

Larger rival Pernod Ricard (EPA:PERP) last week reported a bigger-than-expected fall in quarterly sales, caused partly by weakness in China while luxury giant LVMH, owner of Hennessy cognac, also missed estimates for its third quarter sales, again pointing to China.

($1 = 0.9240 euros)

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Japan stocks lower at close of trade; Nikkei 225 down 0.76%
next post
Exclusive-Europe seeks to underpin Russia sanctions, fearing Trump overhaul

You may also like

Adani, Ambani news units sue OpenAI over copyright,...

March 13, 2026

China’s DeepSeek sets off AI market rout

March 13, 2026

BASF results down on impairments, restructuring

March 13, 2026

Nasdaq futures tumble as China’s AI push rattles...

March 13, 2026

European chipmakers slump as traders gauge DeepSeek AI...

March 13, 2026

Fuji Media, rocked by sexual misconduct allegations, says...

March 13, 2026

China Vanke’s CEO, chairman resign amid growing liquidity...

March 13, 2026

Italy’s MPS shares fall ahead of Mediobanca board...

March 13, 2026

UMG shares rally after new multi-year pact with...

March 13, 2026

British Land stock drops following stake sale

March 13, 2026
Sign up and get the scoop before anyone else—fresh updates, and secret deals, all wrapped up just for you. We're talking juicy tips, fun surprises, and invites to events you actually want to go to. Don’t just watch from the sidelines—jump in and be part of the magic!








    By signing up, you're cool with getting emails from us. Don’t worry — your info stays safe, sound, and strictly confidential. No spam, no funny business. Just the good stuff.

    Recent Posts

    • Trump administration alleges Nike discriminated against white workers

      March 13, 2026
    • Landmark trial accusing social media companies of addicting children to their platforms begins

      March 13, 2026
    • Retail operator of outdoor sportswear pioneer Eddie Bauer files for bankruptcy

      March 13, 2026
    • Cardi B’s cameo in Bad Bunny’s Super Bowl halftime show leads to dispute on prediction markets

      March 13, 2026

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (690)
    • Stock (6,426)

    Latest News

    • Trump administration alleges Nike discriminated against white workers
    • Landmark trial accusing social media companies of addicting children to their platforms begins

    Popular News

    • Kraft Heinz pulls Lunchables meals from US low-income lunch program
    • FDA approves injectable version of Bristol Myers Squibb’s cancer drug Opdivo

    About The Significant deals

    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2026 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy